| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
STAT3 associated genes are often mutated in diffuse large B-cell lymphoma (DLBCL) and their roles as prognostic markers and therapeutic targets were analyzed.
Immunohistochemistry and mutation analysis focusing STAT3 associated genes were performed with FFPE samples from 279 DLBCL patients. Cell of origin was determined with Hans algorithm. Phosphorylated STAT3 (pSTAT3) was detected in 122 cases (44%) and biased toward non-GCB type (P<0.001). MYD88 L265P and EBV positivity were significantly associated with non-GCB type and pSTAT3 expression (P<0.001). STAT3 and non-L265P MYD88 mutations were relatively enriched in GCB type and only the former was significantly associated with pSTAT3 expression (P=0.02). Clinically, pSTAT3 expression and COO was not associated with overall survival. EBV positivity and STAT3 mutations were correlated with poorer and better prognosis, respectively. Our data clarified clinicopathological diversity of STAT3 activation in DLBCL.
|
